Citations

Clear

623 citation(s) found for "Torres, V".

DOP35 Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype
Petralia, Francesca , Sato, Takaya , Li, X-j, Wang, Ping , Telesco, Shannon, Porter, Chad, Laird, Renée M. , Gutiérrez, Ramiro L. , Princen, Fred, Plevy, SE, Strauss, Richard E. , Riddle, Mark S. , Colombel, J F, Group, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study, Choung, Rok Seon , Torres, Joana , Strauss, R, Murray, Joseph A. , Group, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study

Mayo Clinic

Journal of Crohn's and Colitis | January 25, 2019 | Volume: 13 | Issue: Supplement_1 | Pages: S045-S046

10.1093/ecco-jcc/jjy222.069 Get It

Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
Cho, Yeoungjee , Sautenet, Bénédicte , Gutman, Talia , Rangan, Gopala K. , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Coolican, Helen, Kao, Juliana T‐W, Gansevoort, Ron T. , Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, Claire, Oh, Yun Kyu , Teixeira‐Pinto, Armando , Logeman, Charlotte , Howell, Martin , Ju, Angela, Manera, Karine , Tong, Allison , Torres, Vicente E , Johnson, David W , Howell, Martin , Ong, Albert C M , Ahn, Curie , Kao, Juliana Tze‐Wah , Perrone, Ronald D. , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Cho, Yeoungjee

Mayo Clinic

Nephrology | January 21, 2019 | Volume: 24 | Issue: 12 | Pages: 1214-1224

10.1111/nep.13566 | PMID 30663163 Get It

ABSTRACTAimPatients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient‐centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision‐making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.MethodsNominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0–1) for each outcome and conducted thematic analyses.ResultsAcross 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end‐stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.ConclusionFor patients with ADPKD and their caregivers, kidney function, delayed progression to end‐stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient‐important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
Validation of a Metabolite Panel for a More Accurate Estimation of Glomerular Filtration Rate Using Quantitative LC-MS/MS
Freed, Tiffany A., Inker, Lesley A. , Toal, Douglas R., Périchon, Régis, Chen, Jingsha, Goodman, Kelli D., Zhang, Qibo , Conner, Jessie K., Hauser, Deirdre M., Vroom, Kate E.T., Oyaski, Maria L, Wulff, Jacob , Eiríksdóttir, Guðný , Guðnason, Vilmundur , Ford, Lisa A. , Levey, Andrew S. , Coresh, Josef , Torres, Vicente E.

Mayo Clinic

Clinical Chemistry | January 15, 2019 | Volume: 65 | Issue: 3 | Pages: 406-418

10.1373/clinchem.2018.288092 | PMID 30647123 Get It

AbstractBACKGROUNDClinical practice guidelines recommend estimation of glomerular filtration rate (eGFR) using validated equations based on serum creatinine (eGFRcr), cystatin C (eGFRcys), or both (eGFRcr-cys). However, when compared with the measured GFR (mGFR), only eGFRcr-cys meets recommended performance standards. Our goal was to develop a more accurate eGFR method using a panel of metabolites without creatinine, cystatin C, or demographic variables.METHODSAn ultra-performance liquid chromatography–tandem mass spectrometry assay for acetylthreonine, phenylacetylglutamine, pseudouridine, and tryptophan was developed, and a 20-day, multiinstrument analytical validation was conducted. The assay was tested in 2424 participants with mGFR data from 4 independent research studies. A new GFR equation (eGFRmet) was developed in a random subset (n = 1615) and evaluated in the remaining participants (n = 809). Performance was assessed as the frequency of large errors [estimates that differed from mGFR by at least 30% (1 − P30); goal <10%].RESULTSThe assay had a mean imprecision (≤10% intraassay, ≤6.9% interassay), linearity over the quantitative range (r2 > 0.98), and analyte recovery (98.5%–113%). There was no carryover, no interferences observed, and analyte stability was established. In addition, 1 − P30 in the validation set for eGFRmet (10.0%) was more accurate than eGFRcr (13.1%) and eGFRcys (12.0%) but not eGFRcr-cys (8.7%). Combining metabolites, creatinine, cystatin C, and demographics led to the most accurate equation (7.0%). Neither equation had substantial variation among population subgroups.CONCLUSIONSThe new eGFRmet equation could serve as a confirmatory test for GFR estimation.
Acute Kidney Injury in Patients Undergoing Total Hip Arthroplasty: A Systematic Review and Meta-Analysis
Kaewput, Wisit , Thamcharoen, Natanong , Cheungpasitporn, Wisit , Watthanasuntorn, Kanramon , Salim, Sohail Abdul , Ungprasert, Patompong , Lertjitbanjong, Ploypin , Aeddula, Narothama Reddy , Torres‐Ortiz, Aldo, Kaewput, Wisit , Aeddula, Narothama Reddy , Cheungpasitporn, Wisit , Thongprayoon, Charat , Mao, Michael A.

Mayo Clinic

Journal of Clinical Medicine | January 10, 2019 | Volume: 8 | Issue: 1 | Pages: 66

10.3390/jcm8010066 | PMID 30634487 Get It

Background: The number of total hip arthroplasties (THA) performed across the world is growing rapidly. We performed this meta-analysis to evaluate the incidence of acute kidney injury (AKI) in patients undergoing THA. Methods: A literature search was performed using MEDLINE, EMBASE and Cochrane Database from inception until July 2018 to identify studies assessing the incidence of AKI (using standard AKI definitions of RIFLE, AKIN, and KDIGO classifications) in patients undergoing THA. We applied a random-effects model to estimate the incidence of AKI. The protocol for this meta-analysis is registered with PROSPERO (no. CRD42018101928). Results: Seventeen cohort studies with a total of 24,158 patients undergoing THA were enrolled. Overall, the pooled estimated incidence rates of AKI and severe AKI requiring dialysis following THA were 6.3% (95% CI: 3.8%–10.2%) and 0.5% (95% CI: 0.1%–2.3%). Subgroup analysis based on the countries by continent was performed and demonstrated the pooled estimated incidence of AKI following THA of 9.2% (95% CI: 5.6%–14.8%) in Asia, 8.1% (95% CI: 4.9%–13.2%) in Australia, 7.4% (95% CI: 3.2%–16.3%) in Europe, and 2.8% (95% CI: 1.2%–17.0%) in North America. Meta-regression of all included studies showed significant negative correlation between incidence of AKI following THA and study year (slope = −0.37, p <0.001). There was no publication bias as assessed by the funnel plot and Egger’s regression asymmetry test with p = 0.13 for the incidence of AKI in patients undergoing THA. Conclusion: The overall estimated incidence rates of AKI and severe AKI requiring dialysis in patients undergoing THA are 6.3% and 0.5%, respectively. There has been potential improvement in AKI incidence for patients undergoing THA over time.
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert , Connors, Joseph M. , Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Gopal, Ajay K. , Younes, Anas , Engley, Gerald, Manley, Thomas, Fenton, Keenan , Straus, David J. , Gordon, Leo I , Connors, Joseph M , Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J.

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 6 | Pages: 1718-1726

10.1158/1078-0432.ccr-18-2435 | PMID 30617130 Get It

Abstract Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Results: The NA subgroup consisted of 497 subjects in the A+AVD (n = 250) and ABVD (n = 247) arms. Similar to the primary analysis based on the intent-to-treat population, the primary endpoint [modified progression-free survival (PFS) per independent review] demonstrated an improvement among subjects who received A+AVD compared with ABVD (HR = 0.60; P = 0.012). For PFS, the risk of progression or death was also reduced (HR = 0.50; P = 0.002). Subsequent anticancer therapies were lower in the A+AVD arm. Grade 3 or 4 adverse events (AEs) were more common, but there were fewer study discontinuations due to AEs in the A+AVD arm as compared with ABVD. Noted differences between arms included higher rates of febrile neutropenia (20% vs. 9%) and peripheral neuropathy (80% vs. 56%), but lower rates of pulmonary toxicity (3% vs. 10%) in subjects treated with A+AVD versus ABVD. Conclusions: The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Barry, William T., Gabriel, Stacey B., Garraway, Levi A. , Krop, Ian E. , Rimawi, Mothaffar , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2014.32.15_suppl.536 Get It

Transcriptome and epigenome landscape of human cortical development modeled in organoids
Amiri, Anahita , Coppola, Gianfilippo , Scuderi, Soraya , Wu, Feinan , Roychowdhury, Tanmoy , Liu, Fuchen , Pochareddy, Sirisha , Shin, Yurae , Safi, Alexias , Song, Lingyun , Sousa, André M. M. , Crawford, Gregory E. , Šestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M. , An, Joon‐Yong , Armoskus, Christoper, Beach, Thomas G., Belmont, Judson, Bendl, Jaroslav , Borrman, Tyler , Brown, Leanne, Brown, Miguel , Brown, Mimi, Brunetti, Tonya M. , Burke, Emily E., Chae, Yooree, Charney, Alexander W. , Cherskov, Adriana , Choi, Jinmyung , Clarke, Declan , Valle, Diane M. Del , Devillers, Olivia, Dracheva, Stella , Emani, Prashant S. , Evgrafov, Oleg V. , Fitzgerald, Dominic , Flatow, Elie, Francoeur, Nancy , Fullard, John F. , Gao, Tianliuyun , Geschwind, Daniel H. , Giase, Gina , Goodman, Thomas, Grennan, Kay, Gu, Mengting , Hadjimichael, Evi , Hahn, Chang-Gyu, Haroutunian, Vahram , Huey, Jack , Ivanov, Nikolay A. , Jacobov, Rivka, Jiang, Yan , Jiang, Yi , Kassim, Bibi, Kefi, Amira , Kleiman, Joel E., Knowles, James A. , Kozlenkov, Alexey , Li, Zhen , Lipska, Barbara K., Mangravite, Lara M. , Mariani, Jessica , Mattei, Eugenio , Miller, Daniel J. , Moore, J. Russell, Peters, Mette A. , Pinto, Dalila , Polioudakis, Damon, Ray, Mohana, Reddy, Timothy E. , Rhie, Suhn K. , Santpere, Gabriel , Sheppard, Brooke , Shi, Xu , Shieh, Annie W. , Shin, Joo Heon , Spitsyna, Valeria N. , Szatkiewicz, Jin , Szekely, Anna , Wang, Yongjun , Weissman, Sherman M., Weng, Zhiping , White, Kevin P. , Willsey, Jeremy A., Witt, Heather , Won, Hyejung , Xia, Yan , Xu, Min , Yang, Mo , Zandi, Peter P. , Zhang, Jing , Zharovsky, Elizabeth , Sousa, André M M , Gerstein, Mark , Crawford, Gregory E , Sestan, Nenad , Abyzov, Alexej , Vaccarino, Flora M , Del Valle, Diane M , Zhu, Ying , Gerstein, Mark , Akbarian, Schahram , Ashley‐Koch, Allison E. , Bryois, Julien , Camarena, Adrian , Carlyle, Becky Catherine , Chen, Chao , Cheng, Lijun , Collado‐Torres, Leonardo , Dai, Rujia , Torre-Ubieta, Luis de la , Farnham, Peggy , Gandal, Michael J. , Garrett, Melanie E , Girdhar, Kiran Kumar , Giusti‐Rodríguez, Paola , Goes, Fernando , Goodman, Thomas, Gürsoy, Gamze , Hauberg, Mads E. , Hoffman, Gabriel E. , Hyde, Thomas M , Jaffe, Andrew E. , Johnson, Graham D. , Kim, Yunjung , Kitchen, Robert , Li, Mingfeng , Liu, Chunyu , Liu, Shuang , Moore, Jill, Nairn, Angus C. , Navarro, Fábio C. P. , Park, Royce , Pratt, Henry , Price, Amanda J. , Purcaro, Michael J. , Roussos, Panos , Sanders, Stephan , Schreiner, Shannon , Škarica, Mario , State, Matthew W. , Sullivan, Patrick F. , Swarup, Vivek , Tao, Ran , Bakel, Harm van , Wang, Daifeng , Warrell, Jonathan , Webster, Maree J. , Werling, Donna M. , Wiseman, Jennifer R. , Wray, Gregory A. , Yang, Yucheng

Mayo Clinic

Science | December 13, 2018 | Volume: 362 | Issue: 6420 | Pages: No page available

10.1126/science.aat6720 | PMID 30545853 Get It

INTRODUCTION The human cerebral cortex has undergone an extraordinary increase in size and complexity during mammalian evolution. Cortical cell lineages are specified in the embryo, and genetic and epidemiological evidence implicates early cortical development in the etiology of neuropsychiatric disorders such as autism spectrum disorder (ASD), intellectual disabilities, and schizophrenia. Most of the disease-implicated genomic variants are located outside of genes, and the interpretation of noncoding mutations is lagging behind owing to limited annotation of functional elements in the noncoding genome. RATIONALE We set out to discover gene-regulatory elements and chart their dynamic activity during prenatal human cortical development, focusing on enhancers, which carry most of the weight upon regulation of gene expression. We longitudinally modeled human brain development using human induced pluripotent stem cell (hiPSC)–derived cortical organoids and compared organoids to isogenic fetal brain tissue. RESULTS Fetal fibroblast–derived hiPSC lines were used to generate cortically patterned organoids and to compare oganoids’ epigenome and transcriptome to that of isogenic fetal brains and external datasets. Organoids model cortical development between 5 and 16 postconception weeks, thus enabling us to study transitions from cortical stem cells to progenitors to early neurons. The greatest changes occur at the transition from stem cells to progenitors. The regulatory landscape encompasses a total set of 96,375 enhancers linked to target genes, with 49,640 enhancers being active in organoids but not in mid-fetal brain, suggesting major roles in cortical neuron specification. Enhancers that gained activity in the human lineage are active in the earliest stages of organoid development, when they target genes that regulate the growth of radial glial cells. Parallel weighted gene coexpression network analysis (WGCNA) of transcriptome and enhancer activities defined a number of modules of coexpressed genes and coactive enhancers, following just six and four global temporal patterns that we refer to as supermodules, likely reflecting fundamental programs in embryonic and fetal brain. Correlations between gene expression and enhancer activity allowed stratifying enhancers into two categories: activating regulators (A-regs) and repressive regulators (R-regs). Several enhancer modules converged with gene modules, suggesting that coexpressed genes are regulated by enhancers with correlated patterns of activity. Furthermore, enhancers active in organoids and fetal brains were enriched for ASD de novo variants that disrupt binding sites of homeodomain, Hes1, NR4A2, Sox3, and NFIX transcription factors. CONCLUSION We validated hiPSC-derived cortical organoids as a suitable model system for studying gene regulation in human embryonic brain development, evolution, and disease. Our results suggest that organoids may reveal how noncoding mutations contribute to ASD etiology. Summary of the study, analyses, and main results. Data were generated for iPSC-derived human telencephalic organoids and isogenic fetal cortex. Organoids modeled embryonic and early fetal cortex and show a larger repertoire of enhancers. Enhancers could be divided into activators and repressors of gene expression. We derived networks of modules and supermodules with correlated gene and enhancer activities, some of which were implicated in autism spectrum disorders (ASD).
Abstract 124: Nadph Oxidase 4 and Mitochondrial Abnormalities Contribute to Oxidative Stress and Endothelial Dysfunction in Young Normotensive Patients With Autosomal Dominant Polycystic Kidney Disease
Kahveci, Ali, Lerman, Lilach O. , Chebib, Fouad T. , Eirin, Alfonso , Lerman, Amir , Harris, Peter C. , Torres, Vicente E. , Irazabal, María V.

Mayo Clinic

Hypertension | December 6, 2018 | Volume: 72 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.72.suppl_1.124 Get It

Background: Fifty percent of patients with autosomal dominant polycystic kidney disease (ADPKD) present hypertension (HTN) early on, which increases to nearly 100% at end-stage, and is associated with faster renal functional decline. Endothelial dysfunction (ED) accompanied by oxidative stress (OS) precedes the development of HTN, but the mechanisms responsible remain unknown. The aim of this study was to determine whether NADPH oxidase (NOX4) and mitochondrial dysfunction contribute to OS and ED preceding HTN in early ADPKD. Methods: We prospectively measured plasma levels of homocysteine (Hcy), 8-isoprostane, NOX4 and the mtDNA genes COX3 and ND1 in young normotensive (without BP medication) ADPKD patients, and age-matched healthy volunteers (HV) (n=10, each). Total kidney volume (TKV) and Renal Blood Flow (RBF) were evaluated by MRI. Results: BP levels were higher in ADPKD, and HtTKV was twofold higher in ADPKD vs. controls. eGFR and RBF were similar between the groups (Table). Plasma Hcy, 8-isoprostanes and NOX4 were higher in ADPKD, and correlated directly with HtTKV (p<0.05, Figure), but the correlation with RBF was not significant. Plasma mtDNA copy number were lower in ADPKD compared to controls, and correlated inversely with HtTKV(R 2 0.397 and 0.392 respectively). Conclusion: Early ADPKD is associated with elevation in Hcy, 8-isoprostane, and NOX4 levels, and decreased mtDNA copy numbers, which precede the reduction in RBF and the development of HTN, and are associated with disease severity. NOX4 and mitochondrial abnormalities may contribute to oxidative stress, endothelial dysfunction, and possibly the development of HTN and disease progression in ADPKD.
Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider
Unger, Julia , Putrik, Polina , Buttgereit, Frank , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Dias, João Madruga , Falzon, Louise , Gossec, Laure , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Dejaco, Christian , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000756

10.1136/rmdopen-2018-000756 | PMID 30714580 Get It

Objective To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology. Methods A systematic literature review (SLR) was performed in key electronic databases (1946–2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted. Key general as well as specific need/demand and supply factors for workforce calculation in rheumatology were identified. The workforce prediction risk of bias tool was developed and applied to existing workforce studies in rheumatology. Results In total, 14 studies in rheumatology and 10 studies in other medical fields were included. Studies used a variety of prediction models based on a heterogeneous set of need/demand and/or supply factors. Only two studies attempted empirical validation of the prediction quality of the model. Based on evidence and consensus, the newly developed risk of bias tool includes 21 factors (general, need/demand and supply). The majority of studies revealed high or moderate risk of bias for most of the factors. Conclusions The existing evidence on workforce prediction in rheumatology is scarce, heterogeneous and at moderate or high risk of bias. The new risk of bias tool should enable future evaluation of workforce prediction studies. This review informs the European League Against Rheumatism points to consider for the conduction of workforce requirement studies in rheumatology.
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
Dejaco, Christian , Putrik, Polina , Unger, Julia , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Gossec, Laure , Dias, João Madruga , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Buttgereit, Frank , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000780

10.1136/rmdopen-2018-000780 | PMID 30714579 Get It

Objective Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these European League Against Rheumatism (EULAR points to consider (PTC) is to guide future workforce studies in adult rheumatology in order to produce valid and reliable manpower estimates. Methods The EULAR Standardised Operating Procedures were followed. A multidisciplinary task force with experts including patients with rheumatic diseases from 11 EULAR countries and the USA was assembled. A systematic literature review (SLR) was conducted to retrieve workforce models in rheumatology and other medical fields. PTC were based on expert opinion informed by the SLR, followed by group discussions with consensus obtained through informal voting. The level of agreement with the PTC was voted anonymously. Results A total of 10 PTC were formulated. The task force recommends models integrating supply (=workforce available in rheumatology), demand (=health services requested by the population) and need (=health services that are considered appropriate to serve the population). In general, projections of workforce requirements should consider all factors relevant for current and future workload in rheumatology inside and outside of direct patient care. Forecasts of workforce supply should consider demography and attrition of rheumatologists, as well as the effects of new developments in healthcare. Predictions of future need/demand should take demographic, sociocultural and epidemiological development of the population into account. Conclusion These EULAR-endorsed PTC will provide guidance on the methodology and the parameters to be applied in future national and international workforce requirement studies in rheumatology.